Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 54 Stomach Neoplasms 42 Carcinoma, Non-Small-Cell Lung 31 Colorectal Neoplasms 21 Esophageal Squamous Cell Carcinoma 15 Nasopharyngeal Carcinoma 11 Lung Neoplasms 11 Rectal Neoplasms 10 Esophageal Neoplasms 9 Pancreatic Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Small Cell Lung Carcinoma 5 Neoplasms 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Recurrence 4 Neoplasm Metastasis 4 Carcinoma, Renal Cell 4 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Turcot syndrome 2 Thyroid Neoplasms 2 Spinocerebellar Degenerations 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Pemetrexed 9 Drug Therapy 9 osimertinib 7 Radiotherapy 6 Carboplatin 6 anlotinib 5 Radiosurgery 5 aflutinib 4 Gefitinib 4 Docetaxel 4 Cisplatin 4 tislelizumab 3 pembrolizumab 3 icotinib 3 Vinorelbine 3 Paclitaxel 3 Gemcitabine 3 Erlotinib Hydrochloride 3 toripalimab 2 dacomitinib 2 camrelizumab 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Liquid Biopsy 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × sintilimab × Clear all

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡